Louis France, Sabbe Mare, Schleich Florence, Philippe Geneviève, Louis Renaud
Département de pharmacie, ULiège, Belgique.
Service de Pneumologie, CHU Liège, Belgique.
Rev Med Liege. 2024 Dec;79(12):807-811.
Benralizumab is a monoclonal antibody directed toward the α subunit of the interleukin-5 receptor. This drug has been established as a key treatment for severe hypereosinophilic asthma. Here we report results of the PROMISE study, an observational study conducted in 73 severe asthmatic patients treated at the asthma clinic of CHU Liège and whose blood eosinophil count was > 300/µl. After 6 months of treatment, benralizumab reduced exacerbation rate by 92 % and oral corticoid maintenance dose by 83 %, and significantly improved asthma control and quality of life. These effects were maintained over a 18-month time period. These clinical effects were associated with blood and airway depletion in eosinophils but not with a reduction in FeNO (fractional exhaled nitric oxide). The PROMISE study confirms the effectiveness of benralizumab in severe eosinophilic asthmatic patients.
贝那利珠单抗是一种针对白细胞介素-5受体α亚基的单克隆抗体。该药物已被确立为重度嗜酸性粒细胞性哮喘的关键治疗药物。在此，我们报告PROMISE研究的结果，这是一项在列日大学医院哮喘诊所接受治疗的73例重度哮喘患者中进行的观察性研究，这些患者的血液嗜酸性粒细胞计数>300/µl。治疗6个月后，贝那利珠单抗使急性加重率降低了92%，口服糖皮质激素维持剂量降低了83%，并显著改善了哮喘控制和生活质量。这些效果在18个月的时间内得以维持。这些临床效果与血液和气道中嗜酸性粒细胞的减少有关，但与呼出一氧化氮分数（FeNO）的降低无关。PROMISE研究证实了贝那利珠单抗在重度嗜酸性粒细胞性哮喘患者中的有效性。
